# Atezolizumab

## Tecentriq inj 1200mg/20mL

| TAH Drug Code      | [ITEC](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITEC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Non-Small Cell Lung Cancer (NSCLC)** - Monotherapy for stage II to IIIA NSCLC (UICC/AJCC 7th edition) with PD-L1 expression (TC ? 1%) as adjuvant therapy after tumor resection and platinum-based chemotherapy. - Monotherapy for locally advanced or metastatic NSCLC that has progressed after platinum-based chemotherapy. Patients with EGFR or ALK tumor mutations must first receive appropriate targeted therapy before using this drug. - Combination therapy with bevacizumab， paclitaxel， and carboplatin as first-line treatment for metastatic non-squamous NSCLC. Patients with EGFR or ALK-positive tumors must first receive targeted therapy before using this combination. - Combination therapy with nab-paclitaxel and carboplatin as first-line treatment for metastatic non-squamous NSCLC without EGFR or ALK mutations. - Monotherapy as first-line treatment for metastatic NSCLC without EGFR or ALK mutations， with high PD-L1 expression (TC ? 50% or IC ? 10%). - Monotherapy as first-line treatment for locally advanced or metastatic NSCLC without EGFR or ALK mutations and unsuitable for platinum-based chemotherapy. 2. **Triple-Negative Breast Cancer (TNBC)** - Combination therapy with nab-paclitaxel for unresectable locally advanced or metastatic TNBC with PD-L1 expression (IC ? 1%) in patients who have not received prior chemotherapy for metastatic disease. 3. **Small Cell Lung Cancer (SCLC)** - Combination therapy with carboplatin and etoposide as first-line treatment for extensive-stage SCLC in adults. 4. **Hepatocellular Carcinoma (HCC)** - Combination therapy with bevacizumab for unresectable or metastatic HCC in patients who have not received prior systemic therapy and have Child-Pugh A liver function. 5. **Alveolar Soft Part Sarcoma (ASPS)** - Monotherapy for unresectable or metastatic ASPS in patients aged 2 years and older.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | ●Small cell lung cancer， extensive stage， first-line treatment: IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks， in combination with carboplatin and etoposide for 4 cycles， followed by atezolizumab maintenance， as a single agent， until disease progression or unacceptable toxicity ●Non–small cell lung cancer (NSCLC)， metastatic: Single-agent atezolizumab: NSCLC， with PD-L1 expression (PD-L1 stained ?50% of tumor cells [TC ?50%] or PD-L1 stained tumor-infiltrating immune cells covering ?10% [IC ?10%])， first-line treatment: IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks; continue until disease progression or unacceptable toxicity. NSCLC， previously treated: IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks; continue until disease progression or unacceptable toxicity. Combination therapy: Nonsquamous NSCLC， first-line treatment: IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks， in combination with bevacizumab， paclitaxel， and carboplatin for 4 to 6 cycles (ABCP regimen)， followed by atezolizumab and/or bevacizumab maintenance therapy until disease progression or unacceptable toxicity. IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks， in combination with paclitaxel (protein bound) and carboplatin for 4 to 6 cycles， followed by atezolizumab maintenance， as a single agent， until disease progression or unacceptable toxicity. ●Non–small cell lung cancer， adjuvant treatment， with PD-L1 expression (?1%) : IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks， as a single agent; after up to 4 cycles of adjuvant platinum-based chemotherapy; continue atezolizumab for up to 1 year， unless disease recurrence or unacceptable toxicity occurs. ●Alveolar soft part sarcoma， unresectable or metastatic: IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks， as a single agent; continue until disease progression or unacceptable toxicity. ●Triple-Negative Breast Cancer (TNBC): 840 mg every 2 weeks， 1200 mg every 3 weeks， or 1680 mg every 4 weeks. When administered on the same day， Tecentriq must be given before nab-paclitaxel. 100 mg/m2 on Days 1， 8， and 15 of each 28-day cycle， continued until disease progression or unacceptable toxicity occurs. Tecentriq and nab-paclitaxel may be discontinued separately due to toxicity. ●Hepatocellular carcinoma， unresectable or metastatic: IV: 840 mg once every 2 weeks or 1，200 mg once every 3 weeks or 1，680 mg once every 4 weeks， in combination with bevacizumab; continue until disease progression or unacceptable toxicity; may continue beyond disease progression if clinical benefit demonstrated. If bevacizumab is discontinued due to unacceptable toxicity， may continue atezolizumab， as a single agent， until disease progression or unacceptable toxicity. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Hypersensitivity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Common: Hypertension (17-43%)， Alopecia (32-48%)， Rash (0.6-75%)， Constipation (12-36%)， Decrease in appetite (15-30%)， Diarrhea (11-43%)， Nausea (12-50%)， Arthralgia (11-26%)， Asthenia (25-51%)， Neuropathy (33-56%)， Urinary tract infectious disease (<10%)， Cough (Up to 27%)， Dyspnea (Up to 33%)， Fatigue (14-61%) Serious: Myocarditis， Pericarditis， Vasculitis， Erythroderma， Stevens-Johnson syndrome， Toxic epidermal necrolysis， Adrenal insufficiency (0.4-1.2%)， Hyperthyroidism (0.8-18%)， Hypoparathyroidism， Hypophysitis (<0.1%)， Hypothyroidism (4.9-26%)， Thyroiditis (0.2-1.2%)， Type 1 diabetes mellitus (0.3%)， Abdominal pain (12-25%)， Colitis (1%)， Duodenitis， Gastritis， Pancreatitis (<10%)， Aplastic anemia， Hemolytic anemia (Rare)， Hemophagocytic lymphohistiocytosis， Histiocytic necrotizing lymphadenitis， Immune thrombocytopenia， Hepatitis (1.8-6.1%)， Veno-occlusive disease of the liver， Drug reaction with eosinophilia and systemic symptoms， Graft versus host disease， Sarcoidosis， Systemic inflammatory response syndrome， Transplanted organ rejection， Arthritis， Eaton-Lambert syndrome， Myasthenia gravis， Myositis， Polymyalgia rheumatica， Polymyositis， Rhabdomyolysis， Cerebral infarction， Demyelination of spinal cord， Encephalitis， Guillain-Barre syndrome， Meningitis， Myelitis， Iritis， Myasthenia gravis， ocular， Uveitis (<10%)， Visual impairment， Vogt-Koyanagi-Harada disease， Acute renal failure (2.2%)， Nephritis (Up to 1.3%)， Chronic obstructive pulmonary disease， Pneumonitis (3-13%)， Cancer (2.2%)， Disorder characterized by fever， steroid-requiring， Fever (14-49%)， Infectious disease， Inflammatory disease of mucous membrane， Infusion reaction (1.3-11%)， Sepsis， Sepsis due to Staphylococcus， Septic shock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/atezolizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

